Research therapeutics: protein kinase inhibitors - Qurient Therapeutics

Drug Profile

Research therapeutics: protein kinase inhibitors - Qurient Therapeutics

Alternative Names: Axl kinase inhibitors - Qurient Therapeutics; CDK7 inhibitors - Qurient Therapeutics; Cyclin-dependent kinase 7 inhibitors - Quriant Therapeutics; Q-701

Latest Information Update: 14 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Max Planck Innovation; The Lead Discovery Center; The Max Planck Institute of Biochemistry; Vichem Chemie
  • Developer Max Planck Innovation; Qurient Co; The Lead Discovery Center; The Max Planck Institute of Biochemistry
  • Class Anti-inflammatories; Antineoplastics; Antivirals
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • Research Inflammation; Viral infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top